Munich Startup
RNATICS GmbH

RNATICS GmbH

RNATICS develops medicines based on short nucleic acid molecules, so-called oligonucleotides, that target disease-causing RNAs in tissue-resident macrophages. This novel delivery mechanism enables access to organs that have previo...

Founded2021
Business ModelB2B
IndustryBioTech
This content was machine translated.

About RNATICS GmbH

RNATICS develops medicines based on short nucleic acid molecules, so-called oligonucleotides, that target disease-causing RNAs in tissue-resident macrophages. This novel delivery mechanism enables access to organs that have previously been inaccessible for nucleic acid therapies, opening up significant therapeutic potential in many diseases. We plan to start the first clinical trial (Phase I) of our lead candidate, RCS-21, for the treatment of fibrotic lung disease following viral infections (e.g. COVID-19) in spring 2024.

More like this

Discover more articles, startups, and events from the ecosystem

One Week of Coliving: How Coworking Works at Werk1
Inside Stories

One Week of Coliving: How Coworking Works at Werk1

19.08.26
4 Min.
Oceanloop: Up to 38.5 Million Euros for Grouper Farming
Deals

Oceanloop: Up to 38.5 Million Euros for Grouper Farming

19.08.26
2 Min.
A Week of Coliving: In Conversation with the Man Behind Werk1
Inside Stories

A Week of Coliving: In Conversation with the Man Behind Werk1

18.08.26
4 Min.